5 Top Gainers In Healthcare Sector (SINT, JAGX, EVLO…)
The following are some of today’s top gainers in the pharma/biotech sector.
1. Sintx Technologies Inc. (SINT)
SINTX Technologies is a commercial biomaterial company focused on using its silicon nitride technology platform to develop, manufacture and sell a broad range of medical devices.
Gained 41.33% to close Thursday’s (Sep.12) trading at $2.12.
News: The Company has retained Ascendiant Capital Markets, LLC of Irvine, California, Member FINRA & SIPC as investment bank and advisor to identify strategic opportunities in the dental space.
On August 15, 2019, the Company announced financial results for the second quarter ended June 30, 2019, and also revealed that it is now compliant with the minimum bid price requirement for continued listing on the Nasdaq Stock Market.
The revenue for the second quarter of 2019 was $0.2 million compared to nil revenue in the year-ago quarter. The loss from continuing operations for the recent second quarter was $0.73 million or $1.46 per share compared to a loss from continuing operations $2.181 million or $12.06 per share in the year-ago quarter.
As of June 30, 2019, the Company had cash and cash equivalents of $3.2 million.
2. Jaguar Health Inc. (JAGX)
Jaguar Health is a commercial-stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products for humans and animals. Revenue is derived from the sale of Mytesi, an anti-diarrheal indicated for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy.
Gained 20.91% to close Thursday’s trading at $1.33.
News: No news
The Target Animal Safety technical section, which is the last of the four technical sections, related to the Company’s application for Crofelemer delayed-release tablets (Canalevia) for the indication of chemotherapy-induced diarrhea (CID) in dogs is due to be submitted to the FDA’s Center for Veterinary Medicine this quarter.
3. EyeGate Pharmaceuticals Inc. (EYEG)
EyeGate Pharma is a clinical-stage company focused on developing products for treating disorders of the eye.
Gained 20.47% to close Thursday’s trading at $3.59.
News: No news
Clinical Trials & Near-term Catalysts:
The lead product candidate is Ocular Bandage Gel (OBG), a unique, first-in-class eye drop formulation, currently in clinical development for two indications – Photorefractive Keratectomy (PRK) surgery and Punctate Epitheliopathies (PE).
— A pivotal study of Ocular Bandage Gel in photorefractive keratectomy is underway, with topline results expected by year-end 2019, after which the Company plans to submit the de novo application for commercialization.
— Enrollment in a follow-on pilot study of Ocular Bandage Gel for punctate epitheliopathies is scheduled to begin in the near future, with topline results expected by year-end 2019.
4. Prevail Therapeutics Inc. (PRVL)
Prevail is a biotechnology company developing AAV-based gene therapies for patients with neurodegenerative disorders.
Gained 16.94% to close Thursday’s trading at $10.77.
News: No news
Pipeline & Near-term Catalysts:
The Company’s pipeline includes PR001 that is being developed as a potentially disease-modifying, single-dose gene therapy for Parkinson’s disease with GBA1 mutation (PD-GBA) and neuronopathic Gaucher disease; PR006, a gene therapy candidate being developed for patients with frontotemporal dementia with a GRN mutation (FTD-GRN), and PR004, a gene therapy in preclinical development for patients with certain synucleinopathies.
— Patient dosing in a Phase 1/2 clinical trial of PR001 in PD-GBA is on track to be initiated this year.
— Enrollment in a Phase 1/2 trial of PR001 in neuronopathic Gaucher disease is expected to begin in the first half of 2020.
— A Phase 1/2 clinical trial of PR006 in patients with frontotemporal dementia with a GRN mutation (FTD-GRN) is expected to be initiated in the first half of 2020.
5. Evelo Biosciences Inc. (EVLO)
Evelo Biosciences is a clinical-stage company pioneering the development of monoclonal microbials to treat all stages of major chronic diseases and cancer.
Gained 16.89% to close Wednesday’s trading at $7.89.
News: No news
The Company has three drugs in clinical development:
— EDP1066 under phase 1b trial in Atopic Dermatitis or Psoriasis
— EDP1815, which has successfully completed phase 1b trial in Psoriasis
— EDP1503 under phase 1/2 trials in colorectal carcinoma, Triple-negative breast cancer, and PD-1 relapsed cancers. EDP1503 is also under a phase IIa investigator-sponsored study by the University of Chicago in the indication of melanoma.
— Evelo is focusing the current EDP1066 Phase 1b trial on investigating the activity of a new formulation, which was up to 30-fold more potent in preclinical models, in a cohort of mild to moderate atopic dermatitis patients. Evelo expects to report data from this cohort in the first quarter of 2020.
— A phase II trial of EDP1815 in mild to moderate psoriasis patients is expected to be initiated in early 2020.
— Initial clinical data from the Phase 1/2 clinical trial of EDP1503 in combination with Merck’s KEYTRUDA, in microsatellite stable colorectal cancer, triple-negative breast cancer, and patients with other tumor types that have relapsed on prior PD-1/L1 inhibitor treatment is expected in the first half of 2020.
Source: Read Full Article